ClinicalTrials.gg
RecruitingNCT03372317Updated Feb 11, 2026

Tau PET in Imaging and Cognition: Healthy Adults From 55-90

An observational study in Mild Cognitive Impairment and Aging, sponsored by Yaakov Stern. Recruiting at 1 site in United States. Open to participants aged 55 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by Yaakov Stern · Observational

How we know

From the registry’s dates

  • Started Jun 2018; still recruiting 8 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
105
Ages
55 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,421 studies in Cognitive Dysfunction with a site in United States — 328 open to participants now, 431 under way, 13 of them phase 3. Cognitive Dysfunction · United States.

Planned enrollment
153rd of 270
105 · median 150
Started
2018
with 83 others
Observational
270 of 1,421
67 open now
Primary completion
2027-01
later than 152 of 430 live
Registered
526th of 1,421
by date

Among the 1,421 studies in Cognitive Dysfunction with a site in United States, this one is the 153rd largest by planned enrollment of the 270 observational ones that give a count, is one of 84 that started in 2018, is one of 270 observational ones, reaches primary completion later than 152 of the 430 other live ones, and was the 526th registered.

Cognitive Dysfunction

3,881 studies on the registry are indexed under Cognitive Dysfunction; 1,121 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

328 of the 1,421 studies in Cognitive Dysfunction with a site in United States are open now. Recruiting first, the newest first:

323 more — sign in →

All 328 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 752 Cognitive Dysfunction studies recruiting now, 362 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 55 Years to 90 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,421 studies in Cognitive Dysfunction with a site in United States, or all of them as a file.
02

Study summary

The investigators aim to use the new PET radioligand, 18F-MK-6240, to detect tau pathology in cognitive healthy and mild cognitive impairment (MCI) elders. The investigators will then examine the interactions between differential tau burden and performance on cognitive tasks, functional magnetic resonance imaging (fMRI) neural activation patterns, and other cognitive and behavioral measures. By investigating these relationships, the investigators hope to understand the cognitive and behavioral outcomes of tau deposition found in specific brain regions in cognitively normal/mildly cognitively impaired adults. Furthermore, the study aims to examine how the presence of tau may contribute to the risk of subsequent cognitive decline, neurodegeneration, and dementia.

Read the detailed description

Many cognitively healthy older adults have, upon post mortem evaluations, been found to have varying amounts of neurofibrillary tangles (tau) and beta-amyloid plaque deposits, which are the hallmark brain pathologies known to be associated with Alzheimer's disease and various other dementias. While some with these pathologies may not clinically express cognitive decline or dementia in their lifetime, human post-mortem studies suggest that increasing neurofibrillary tangle density correlates with neurodegeneration and cognitive impairment.

Imaging tauopathy in-vivo provides an opportunity to examine neurocognitive correlates of differential levels of tauopathy in the brain, allowing to further qualify pre-clinical states of cognitive impairment. The investigators aim to investigate possible protective mechanisms, such as cognitive reserve, that may modulate the relationship between tauopathy and cognitive decline.

03

Conditions studied

  • Mild Cognitive Impairment
  • Aging

Keywords

  • Tau
  • MK-6240
  • Cognition
04

Who can participate

Ages eligible
55 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Subjects, 55-90 years old that previously received an amyloid PET scan

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 55-90
  • Previously received an amyloid PET scan
  • Residing near Columbia University Medical Center
  • Must be willing and able to participate

Exclusion criteria

Exclusion Criteria:

  • Have a to PET (e.g, metallic implants, pacemaker, claustrophobia, or cannot lie flat for one hour)
  • Pregnancy
  • Lactating Women
  • Current, past, or anticipated exposure to radiation
  • Significant active physical illness
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
105 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Non-demented elders

    Participants aged 55-90 that are cognitively normal or have mild cognitive impairment will receive 18F-MK-6240 to identify the presence of tau protein in the brain.

    Drug: 18F-MK-6240

Interventions

  • Drug18F-MK-6240

    Results of the 18F-MK-6240 PET scan will be correlated with other observations.

    Also known as: 6-[18F]Fluoro-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine

06

What researchers measure

Primary outcomes

  1. Total number of individuals with tau present

    Based on the scans, the total number of subjects with identifiable tau in their scans will be measured.

    Time frame: Up to 5 years

  2. Cognition

    Relation of Tau PET to measures of cognition such as memory and reasoning

    Time frame: Up to 5 years

  3. Functional imaging (fMRI)

    Relation of Tau PET to imaging acquired during task performance

    Time frame: Up to 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified data could be shared based on NIH regulations

Time frame: Study data will be available within 1 year

Access criteria: We will be sharing de-identified data with a consortium that is aggregating studies that have employed tau PET tracers

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2018 (actual). Primary completion is estimated for Jan 2027, 103 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2017
First posted
Dec 13, 2017
StartActual
Jun 1, 2018
Primary completionEst.
Jan 2027
CompletionEst.
Dec 2027
Last update
Feb 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03372317
Lead sponsor
Yaakov Stern
Responsible party
Yaakov Stern (Professor of Neuropsychology, Columbia University) — Sponsor-investigator
First posted
Dec 13, 2017
Start date
Jun 1, 2018
Primary completion
Jan 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Feb 11, 2026

Study contacts

Reshma Babukutty
Contact
rb2996@cumc.columbia.edu
212-305-6314
Yaakov Stern, PhD
principal investigator · Columbia University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion